Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Dec;13(4):496-504.
doi: 10.20892/j.issn.2095-3941.2016.0066.

Ki-67 as a prognostic marker according to breast cancer molecular subtype

Nahed A Soliman  1 , Shaimaa M Yussif  2
Affiliations

Ki-67 as a prognostic marker according to breast cancer molecular subtype

Nahed A Soliman et al. Cancer Biol Med. 2016 Dec.

Abstract

Objective: Ki-67 plays an important function in cell division, but its exact role is still unknown. Moreover, few works regarding its overall function were published. The present study evaluated the clinical significance of Ki-67 index as a prognostic marker and predictor of recurrence in different molecular subtypes of breast cancer. The relationship of Ki-67 index with different clinicopathological factors was also analyzed.

Methods: Ki-67 index was measured in 107 cases of primary breast cancer from 2010-2012. These patients were evaluated for estrogen receptor, progesterone receptor, and HER2. Ki-67 was divided according to percentage levels: < 15% and > 15%. Follow-up ranged from 32 months up to 6 years.

Results: Approximately 44, 23, 15, and 25 cases were grouped as luminal A, luminal B, HER2 subtype, and triple-negative (TN), respectively. No luminal A patients showed Ki-67 level higher than 15%, and their recurrence was 20%. In luminal B group, Ki-67 level higher than 15% was observed in 69% of patients, and recurrence was 39%. In HER2 subtype, Ki-67 was higher than 15% in 34% of cases, and recurrence was 40%. In triple-negative cases, Ki-67 was higher than 15% in 60% of cases, and recurrence was detected in 32% of patients. Patients with Ki-67 less than 15% displayed better overall survival than those with Ki-67 higher than 15% (P = 0.01). Patients with Ki-67 higher than 15% exhibited higher incidence of metastasis and recurrence than those with Ki-67 less than 15% (P = 0.000).

Conclusions: Ki-67 may be considered as a valuable biomarker in breast cancer patients.

Keywords: Ki-67; breast cancer; molecular subtypes; prognostic.

PubMed Disclaimer

Figures

1
1
Nuclear positivity for Ki-67 in more than 15% of tumor cells with variable staining intensity (IHC, 400×).
2
2
Survival curves of breast cancer patients. Patients with Ki-67 < 15% have better OS than those with Ki-67 > 15% (P = 0.012, HR 6.3)
3
3
Disease free survival of breast cancer patients. Patients with Ki-67 > 15% are more likely to develop recurrence and distant metastasis than those with Ki-67 < 15% (P = 0.000, HR 30.47).
See this image and copyright information in PMC

References

    1. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA. 2006;295:2492–502. - PubMed
    1. Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, et al. Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades. Cancer Epidemiol Biomarkers Prev. 2012;21:1848–55. - PMC - PubMed
    1. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52. - PubMed
    1. Perou CM, Børresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol. 2011;3:pii: a003293. - PMC - PubMed
    1. Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med. 2010;7:e1000279. - PMC - PubMed